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n a story entitled “Boston Scientific Stent Study Flawed” that
ppeared in the August 14, 2008, issue of the Wall Street Journal
1), reporter Keith J. Winstein questions the statistical methodol-
gy used in the TAXUS ATLAS trial to show noninferiority of
arget vessel revascularization (TVR) for the newer thinner-strut
axus Liberté stent relative to a historical Taxus Express control
tent, as published in the Journal (2).
Although the Taxus Liberté patients in the study proved to be
ignificantly more complex than the historical Taxus Express study
ontrol patients, the unadjusted rates of the clinical primary end
oint showed a 0.94% difference (7.95% for Taxus Liberté and
.01% for the Taxus Express control) (2). To show noninferiority
equired the 1-sided upper 95% confidence interval of this small
ifference to not exceed the pre-specified delta of 3.0%, using the
ethods as defined in both the study protocol and the statistical
nalysis plan approved by the U.S. Food and Drug Administration
FDA) before the study began.Figure 1 Noninferiority TestBecause the methods for data analysis in the statistical
nalysis plan were not detailed in the published article, we have
eproduced them herein (Fig. 1). As applied to source-verified
atient outcomes adjudicated by an independent Clinical
vents Committee and reviewed by the FDA, the upper 1-sided
5% confidence interval for the unadjusted TVR difference was
.98% (i.e., not exceeding 3.0), with a p value of 0.0487
sufficient to reject the null hypothesis and accept the alternate
ypothesis of noninferiority).
The point raised by Mr. Winstein centers on the mathematical
recision of this specific statistical method used for noninferiority
rials in general. He suggests that, had alternative mathematical
ests been used, p values up to 0.051 might have been calculated.
lthough this may be mathematically interesting, it is clinically
rrelevant to use other post hoc methods of calculation. An
cceptable method (3) was pre-specified in the FDA-approved
tatistical analysis plan. To apply other alternative statistical
ethodologies would be grossly inappropriate, a violation of the
undamental scientific contract to adhere to the original trial
esign and the associated statistical analysis plan specified before
he study commenced.
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January 20, 2009:296–7Should different types of analysis be mandated by the FDA in
he future, investigators and industry sponsors will design trials to
eet these requirements.
Accordingly, the authors stand firmly behind the findings
rom the TAXUS ATLAS workhorse trial that the unadjusted
VR for the Taxus Liberté stent is noninferior to that of the
arlier Taxus Express stent. This is expected for 2 stent designs
hat use identical drug and polymer coatings and provide
dentical reduction in excess tissue growth within the stent (late
oss 0.41 mm for Taxus Liberté and 0.42 mm for Taxus
xpress) (2). The small apparent difference in unadjusted TVR
hus likely reflects the significantly greater complexity of the
AXUS ATLAS patients compared with the historical control
ubjects; the TVR rates become nearly identical (adjusted TVR
.82% for Taxus Liberté and 7.48% for Taxus Express, nonin-
eriority p value 0.0276) when corrected for the measurable
aseline differences between the respective study populations.
dditionally, results from the real-world OLYMPIA (Global
AXUS Liberté Registry Program to Support Worldwide Commer-
ialization) registry in more than 7,000 Taxus Liberté patients treated
ithout routine angiographic follow-up shows a 1-year target lesionevascularization rate of 2.5% (4).Mark A. Turco, MD, FACC, FSCAI
ohn A. Ormiston, MBChB
Center for Cardiac and Vascular Research
ashington Adventist Hospital
600 Carroll Avenue, 6th Floor
akoma Park, Maryland 20912
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